Provide tailored commercial advisory services specializing in commercialization support for start-ups and small biotech companies including strategic, tactical and operational planning.

Provide cross-functional leadership across marketing, medical affairs, sales, legal, finance, regulatory, and corporate communications to achieve brand objectives. Lead marketing with team of 5 across multiple segments (HCP, Patient, and Payer) to support revenue and profitability growth. • Developed new sales campaigns and tools for HCPs and patients, boosting INBRIJA sales by 36% in 2023 to $33.6M despite cost containment pressures, while maintaining post-patent AMPYRA sales of $63.9M.• Led US marketing for INBRIJA and AMPYRA, managed international partnerships, onboarded teams, and coordinated global marketing initiatives; oversaw $4.8M in partnership-generated INBRIJA revenue, contributing to $38.4M total worldwide net revenue in 2023.• Streamlined marketing operations by consolidating into single third-party marketing agency, reducing management fees by 50% from $400K to $200K; reinvested savings to expand brand reach, optimizing $4M budget allocation and vendor management.• Implemented AI tool for MLR review, ensuring consistency and freeing marketing team focus for higher-value tasks; enhanced efficiency and maintained regulatory compliance across all promotional materials.• Repurposed HCP campaign footage to create cost-effective TV commercial, leveraging affordable streaming ads; facilitated execution of initiative, leading to 148 new prescribers and over 300 new prescriptions for INBRIJA within 8 months, accelerating brand adoption.

Directed new product planning for diverse portfolio of pipeline drugs, including treatments for heart failure, multiple sclerosis, Parkinson’s disease, epilepsy, Parkinson’s disease dementia and migraine. Directed pre-approval market preparation for epilepsy (not FDA-approved) and Parkinson’s disease (INBRIJA) launches. Managed a $25M budget and team of 6. • Addressed higher-than-expected reports of coughing for INBRIJA by developing improved training materials and promotion of new nurse support program, resulting in over 1.2K patients returning or starting therapy and increasing prescription conversion rates from 46% to 70%.• Developed comprehensive KOL strategy for epilepsy drug launch, leveraging Sunshine Transparency Act data to identify top 57 speakers; created efficient plan to train 40 promotional speakers within 45 days of FDA approval, enhancing launch readiness despite ultimate non-approval.• Assumed oversight of INBRIJA launch preparation, implementing workshops and cross-functional planning; developed phased timeline for resources, coordinated multiple agencies, and ensured readiness for early FDA approval, achieving on-time delivery of all materials and enabling prompt sales team training and promotion.• Proactively flew to South San Francisco post-acquisition to build trust with new biotech team, facilitating strong relationships and inclusion in commercial brand planning; ensured team buy-in and collaboration.• Led impactful pre-approval disease state educational campaign for epilepsy product, overcoming internal resistance to execute successful HCP engagement; increased registered HCP database users tenfold, from 188 to 1,822, enhancing launch readiness despite ultimate non-approval.

Selected to turnaround speaker’s bureau, consisting of 210 speakers performing 1K+ speaker programs annually with $3.5M budget. Developed and implemented new processes to improve program quality and outcomes. • Led transition to new speaker's bureau management vendor, addressing compliance issues and preparing for portfolio expansion; managed cross-functional team, vendor selection, and implementation, ensuring improved data management and regulatory compliance for 1K+ annual programs.• Enhanced consumer engagement by introducing patient ambassadors to speaker programs, overcoming attendance challenges; secured legal and compliance approval, partnered with specialized firm, and trained ambassadors, enriching program appeal and boosting attendance.

Led US marketing preparations for pre-registration epilepsy drug launch. Co-chaired cross-functional Launch Readiness team and 3 strategic steering teams for pipeline products. Provided commercial input for strategic planning, development, and evaluation of new products. • Established process for integrating commercial success requirements into development planning; organized workshop with external expert to align teams on Target Product Profiles. • Initiated and led Human Factors Engineering study for epilepsy drug-device combination, ensuring FDA compliance; managed cross-functional team, coordinated with external consultants, and oversaw 3 testing rounds with 68 participants, preventing potential FDA application refusal and program delays.• Provided commercial support for business development by identifying co-promotion opportunities outside neurology; analyzed sales force capacity and researched specialist groups, presenting list of potential assets and excess capacity analysis to senior leadership.

Delivered strategic marketing consulting services, focusing on new product planning, marketing & brand strategy, and comprehensive market analysis. Conducted in-depth market research to inform strategic decision-making and identify growth opportunities for a start-up biotech firm.

Directed the commercial integration of an in-licensed drug from a small biotech company and oversaw the initial global brand preparations in a new therapeutic area for the company. ● Drove the alignment of commercial strategies with broader development goals through effective leadership of the alliance's Joint Development Committee.● Orchestrated the creation of a global brand plan and lifecycle strategy, integrating input from global functions and affiliate marketing teams within six months.

Drove the acquisition of strategic assets by performing detailed market analyses and forecasting trends. Fostered cross-functional collaboration to create comprehensive marketing strategies that addressed unmet medical needs and supported business development initiatives.